• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Prestige Consumer Healthcare Inc.

    1/23/25 3:55:50 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBH alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 6)


    Prestige Consumer Healthcare Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    74112D101

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    74112D101


    1Names of Reporting Persons

    Dimensional Fund Advisors LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,827,065.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,907,066.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,907,066.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.9 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Prestige Consumer Healthcare Inc
    (b)Address of issuer's principal executive offices:

    660 White Plains Road, Suite 250, Tarrytown, NY 10591
    Item 2. 
    (a)Name of person filing:

    Dimensional Fund Advisors LP
    (b)Address or principal business office or, if none, residence:

    6300 Bee Cave Road, Building One, Austin, TX 78746
    (c)Citizenship:

    Delaware Limited Partnership
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    74112D101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,907,066 ** see Note 1 ** ** Note 1 ** Dimensional Fund Advisors LP, an investment adviser registered under Section 203 of the Investment Advisors Act of 1940, furnishes investment advice to four investment companies registered under the Investment Company Act of 1940, and serves as investment manager or sub-adviser to certain other commingled funds, group trusts and separate accounts (such investment companies, trusts and accounts, collectively referred to as the "Funds"). In certain cases, subsidiaries of Dimensional Fund Advisors LP may act as an adviser or sub-adviser to certain Funds. In its role as investment advisor, sub-adviser and/or manager, Dimensional Fund Advisors LP or its subsidiaries (collectively, "Dimensional") may possess voting and/or investment power over the securities of the Issuer that are owned by the Funds, and may be deemed to be the beneficial owner of the shares of the Issuer held by the Funds. However, all securities reported in this schedule are owned by the Funds. Dimensional disclaims beneficial ownership of such securities. In addition, the filing of this Schedule 13G shall not be construed as an admission that the reporting person or any of its affiliates is the beneficial owner of any securities covered by this Schedule 13G for any other purposes than Section 13(d) of the Securities Exchange Act of 1934.
    (b)Percent of class:

    5.9  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    2,827,065** see Note 1 **

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    2,907,066** see Note 1 **

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Funds described in Note 1 above have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the securities held in their respective accounts. To the knowledge of Dimensional, the interest of any one such Fund does not exceed 5% of the class of securities. Dimensional Fund Advisors LP disclaims beneficial ownership of all such securities.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Dimensional Fund Advisors LP
     
    Signature:Selwyn Notelovitz
    Name/Title:Global Chief Compliance Officer
    Date:01/23/2025
    Get the next $PBH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PBH

    DatePrice TargetRatingAnalyst
    12/9/2024$90.00Buy → Neutral
    Sidoti
    6/21/2024$65.00 → $93.00Neutral → Buy
    DA Davidson
    11/17/2022$71.00Buy
    Canaccord Genuity
    5/10/2022$65.00 → $70.00Hold → Buy
    Jefferies
    5/9/2022$63.00Perform → Outperform
    Oppenheimer
    3/11/2022$156.00 → $142.00Outperform
    BMO Capital
    11/15/2021$61.00 → $63.00Neutral
    DA Davidson
    11/5/2021$123.00 → $126.00Sector Perform
    RBC Capital
    More analyst ratings

    $PBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Prestige Consumer downgraded by Sidoti with a new price target

      Sidoti downgraded Prestige Consumer from Buy to Neutral and set a new price target of $90.00

      12/9/24 9:05:37 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prestige Consumer upgraded by DA Davidson with a new price target

      DA Davidson upgraded Prestige Consumer from Neutral to Buy and set a new price target of $93.00 from $65.00 previously

      6/21/24 7:05:28 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Prestige Consumer with a new price target

      Canaccord Genuity initiated coverage of Prestige Consumer with a rating of Buy and set a new price target of $71.00

      11/17/22 7:23:24 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBH
    Leadership Updates

    Live Leadership Updates

    See more
    • Better For You Wellness Announces Results from Its February 5, 2022, Board of Directors Meeting

      Better For You Wellness Establishes Strategic Advisory Committee with Industry Leaders and MoreColumbus, Ohio--(Newsfile Corp. - February 10, 2022) - Better For You Wellness, Inc. (OTCQB:BFYW) ("Better For You Wellness" or the "Company"), an Ohio-based company focused on the rapidly-growing $1.5T wellness industry, is pleased to announce the results of the Meeting of the Board of Directors that took place on February 5, 2022, via video conference (the "Board Meeting"). The seven members of the Company's Board of Directors (the "Board") include Ian James, Stephen Letourneau, Montel Williams, Christina Jefferson, Joseph Watson, David Deming, and Dr. Nicola Finley, MD.Establishment of Strategic

      2/10/22 3:58:00 PM ET
      $LEAF
      $PBH
      $SPTN
      EDP Services
      Technology
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings

      Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal 2025; Adjusted fiscal 2025 Diluted EPS of $4.52 grew 7.4% versus adjusted prior yearReduced leverage to 2.4x at year-end driven by strong free cash flow and EBITDA growthInitial fiscal 2026 organic revenue growth and Diluted EPS outlook of approximately 1% to 2% and $4.70 to $4.82, respectively TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) --  Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025. "We are very pleased with our fiscal year results, wh

      5/8/25 7:09:10 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings

      Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal 2025; Adjusted fiscal 2025 Diluted EPS of $4.52 grew 7.4% versus adjusted prior yearReduced leverage to 2.4x at year-end driven by strong free cash flow and EBITDA growthInitial fiscal 2026 organic revenue growth and Diluted EPS outlook of approximately 1% to 2% and $4.70 to $4.82, respectively TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) --  Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025. "We are very pleased with our fiscal year results, which

      5/8/25 6:00:00 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prestige Consumer Healthcare to Release Fiscal 2025 Fourth Quarter and Year-End Earnings Results

      TARRYTOWN, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 fourth quarter and year-end earnings release on Thursday, May 8, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10

      4/10/25 5:00:00 PM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Lombardi Ronald M. covered exercise/tax liability with 2,305 shares, decreasing direct ownership by 0.66% to 346,529 units (SEC Form 4)

      4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

      5/9/25 5:46:21 PM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Marketing & Sales Mekhail Adel covered exercise/tax liability with 457 shares, decreasing direct ownership by 2% to 20,908 units (SEC Form 4)

      4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

      5/9/25 5:44:53 PM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: CFO & COO Sacco Christine was granted 7,775 shares and covered exercise/tax liability with 990 shares, increasing direct ownership by 13% to 58,465 units (SEC Form 4)

      4/A - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

      5/9/25 5:43:10 PM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBH
    SEC Filings

    See more
    • SEC Form 10-K filed by Prestige Consumer Healthcare Inc.

      10-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)

      5/9/25 6:06:00 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prestige Consumer Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)

      5/8/25 6:04:33 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Prestige Consumer Healthcare Inc.

      SCHEDULE 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

      2/7/25 7:43:30 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Prestige Consumer Healthcare Inc.

      SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

      2/14/24 10:11:25 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Prestige Consumer Healthcare Inc.

      SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

      2/14/24 7:09:49 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Prestige Consumer Healthcare Inc. (Amendment)

      SC 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

      2/13/24 5:12:15 PM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBH
    Financials

    Live finance-specific insights

    See more
    • UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings

      Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal 2025; Adjusted fiscal 2025 Diluted EPS of $4.52 grew 7.4% versus adjusted prior yearReduced leverage to 2.4x at year-end driven by strong free cash flow and EBITDA growthInitial fiscal 2026 organic revenue growth and Diluted EPS outlook of approximately 1% to 2% and $4.70 to $4.82, respectively TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) --  Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025. "We are very pleased with our fiscal year results, wh

      5/8/25 7:09:10 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings

      Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal 2025; Adjusted fiscal 2025 Diluted EPS of $4.52 grew 7.4% versus adjusted prior yearReduced leverage to 2.4x at year-end driven by strong free cash flow and EBITDA growthInitial fiscal 2026 organic revenue growth and Diluted EPS outlook of approximately 1% to 2% and $4.70 to $4.82, respectively TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) --  Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025. "We are very pleased with our fiscal year results, which

      5/8/25 6:00:00 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prestige Consumer Healthcare to Release Fiscal 2025 Fourth Quarter and Year-End Earnings Results

      TARRYTOWN, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 fourth quarter and year-end earnings release on Thursday, May 8, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10

      4/10/25 5:00:00 PM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care